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Abstract
Implementation of care bundles for prevention of ventilator-associated pneumonia (VAP) and its impact on patient outcomes requires
validation with long-term follow-up. A collaborative multi-centre cohort study was conducted in ﬁve Spanish adult intensive-care units.
A care bundle approach based on ﬁve measures was implemented after a 3-month baseline period, and compliance, VAP rates, inten-
sive-care unit length of stay (ICU LOS) and duration of mechanical ventilation were prospectively recorded for 16 months. There were
149 patients in the baseline period and 885 after the intervention. Compliance with all measures after intervention was <30% (264/
885). In spite of this, VAP incidence decreased from 15.5% (23/149) to 11.7% (104/885), after the intervention (p <0.05). This reduction
was signiﬁcantly associated with hand hygiene (OR = 0.35), intra-cuff pressure control (OR = 0.21), oral hygiene (OR = 0.23) and seda-
tion control (OR = 0.51). Use of the care bundle was associated with an incidence risk ratio of VAP of 0.78 (95% CI 0.15–0.99). We
documented a reduction of median ICU LOS (from 10 to 6 days) and duration of mechanical ventilation (from 8 to 4 days) for patients
with full bundle compliance (intervention period). Efforts on VAP prevention and outcome improvement should focus on achieving
higher compliance in hand and oral hygiene, sedation protocols and intracuff pressure control.
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Introduction
Implementing care bundles in clinical practice has been
widely advocated in mechanically ventilated patients admitted
to an intensive-care unit (ICU) and is associated with a
reduced risk of ventilator-associated pneumonia (VAP) [1]. A
care bundle identiﬁes a set of key interventions deriving from
evidence-based guidelines that, when implemented, are
expected to improve patients’ health outcomes [2]. The aim
of care bundles is to improve health outcomes by facilitating
and promoting changes in patient care and to encourage
guideline compliance.
The scientiﬁc evidence used during the development of
the current care bundle package was derived from Euro-
pean hospital-acquired pneumonia guidelines [3]. This study
is a validation of the usefulness of care bundles for the
prevention of VAP. We have hypothesized that consistent
implementation of the evidence-based bundles can improve
patient health outcomes. Therefore, the primary objective
was to determine the impact of implementing a care bun-
dle package for VAP prevention on VAP rates and dura-
tion of mechanical ventilation (days of mechanical
ventilation; DMV). Secondary objectives included the deter-
mination of any existing relationship between care bundle
compliance and other outcomes, such as ICU length of
stay (ICU LOS), as well as the assessment of compliance
levels and impact of each individual measure on the risk
of VAP.
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Materials and Methods
This intervention was part of a Catalonian quality improve-
ment collaborative strategy, led by the Department of
Health, Generalitat de Catalunya, in collaboration with the
local Society of Intensive Care (Societat Catalana de Medici-
na Intensiva i Critica—SOCMIC) to promote patient safety
in the ICU, known as the FADO project.
A pan-European committee developed a care bundle
based on the ﬁndings of a previous review of the hospital-
acquired pneumonia and VAP guidelines across Europe [3].
The details of how best to implement particular interven-
tions were tailored to the local situation, with practical
details being speciﬁed for each intervention to ensure deliv-
erability. The approach encouraged participation from all
individuals involved in patient care [4,5]. Details of the care
bundle have been reported elsewhere [6].
The strategies for prevention and management of VAP
were scored, after being evaluated by a European expert and
a multidisciplinary panel. The highest scored strategies were
ranked, selected and presented to a local committee to build
a VAP care bundle on prevention (see Supplementary mate-
rial, Data S1). The SOCMIC invited ﬁve hospitals to imple-
ment the intervention after an observational baseline period
of 3 months. The data collection period was conducted using
designated paper forms and lasted from March 2007 to
December 2008. Standard data collection forms were distrib-
uted across centres.
Potential measures were reviewed and discussed in detail
by the steering committee and those considered most
appropriate for inclusion as VAP care bundle recommenda-
tions were: (i) not implementing ventilator circuit changes
unless clinically indicated [7,8]; (ii) the incorporation of seda-
tion control protocols into patient care [9–11]; (iii) the use
of strict hand hygiene using alcohol-based antiseptic before
manipulating the airways [12]; (iv) oral care with chlorhexi-
dine 0.12% every 8 h [13]; and (v) intra-cuff pressure control
to reduce leakage of oropharyngeal secretions to the lower
airways tract [14]. The protocol was standardized across dif-
ferent centres (Data S2).
Each variable was recorded as dichotomous (yes/no) for
every 8-h period and transferred to an electronic database.
Compliance with measures was self-recorded through a
checklist at the end of each nursing shift. As compliance with
individual measures in the care bundle inevitably varied
between shifts, over a 24-h period, the lowest level of com-
pliance achieved for each variable was recorded in the daily
log to facilitate inter-variable analysis for each patient. It was
predetermined that a selected collaborator would randomly
observe the manner in which measures were followed and
recorded, and we expected this to have minimized the bias
in self-reporting. Interventions such as maintaining optimal
hand hygiene comprised the standard of general infection
control procedures [15]. However, its inclusion in the VAP
care bundle represents an opportunity to audit its compli-
ance and optimize the quality of hand hygiene practices. In
addition, the requirement of not changing ventilator circuits
unless indicated represented an accepted care practice.
Nonetheless, the steering committee believed that including
this established intervention remained appropriate because it
had a high degree of evidence and was associated with cost-
containment.
A local ICU improvement team was established and both
the medical leader and the nurse manager were included.
The teams were trained through conference seminars led by
the study investigators, for standardization of care and edu-
cation purposes. The ICU teams were provided with cards,
brochures and posters to educate their staff. Feedback on
VAP rate was provided in the form of posters, detailing
cumulative incidence of VAP and measure compliance in the
different centres. Every centre was allowed access to their
own data and the coordinating centre owned the overall
data. Teams from each centre attended feedback meetings
where results were exposed; data from all centres were
shown but the identity of the centres was not disclosed. This
model of institutional change emerged from the existing liter-
ature on practical approaches to evidence-based practice
[16]. The study was approved by the Ethics Committee of
the coordinating institution (Joan XXIII University Hospital,
Tarragona: ref. 2006) and informed consent was waived.
VAP was deﬁned as early onset when it developed in the
ﬁrst four DMV, and as late onset when it appeared after the
fourth DMV [17].
Ventilation-associated pneumonia was diagnosed by the
attending physician team, based on standardized deﬁnitions
and methods provided by the CDC [18,19] (see Supplemen-
tary material, Data S3). An independent investigator (intensi-
vist), who was not part of the team caring for the patient made
the ﬁnal diagnosis of pneumonia, using quantitative respiratory
cultures, using standardized thresholds [20–23]. Finally, there
was no other infection control programme implemented con-
comitantly to this study in any of the centres.
Variables
Variables were recorded prospectively. The severity of ill-
ness was assessed by the application of an Acute Physiology
and Chronic Health Evaluation (APACHE II) [24] within 24 h
of ICU admission. The attending nurse recorded, every 8 h,
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the compliance for each variable included in the care bundle.
All other variables were collected by the study coordinator.
Statistical analysis
Data were analysed using statistical software (Version 15.0
for Windows; SPSS, Chicago, IL, USA). Continuous variables
were described as mean values, medians and SDs, and were
compared with Student’s t test or Mann–Whitney U test as
appropriate according to distribution. Categorical variables
were compared with Pearson and, if appropriate, Fisher
exact tests. The signiﬁcance level was deﬁned as p £0.05.
Compliance rates were calculated as (number of cases where
compliance with measure X was observed / total number of
intubated patients in the same period of time) · 100.
Results
The ﬁnal study included a total of 3845 ventilator-days, 149
patients in the baseline period and 885 patients after the
intervention. Characteristics of the study population are
summarized in Table 1. There were no signiﬁcant differences
from the baseline period and intervention period in terms of
percentages of each specialty for all centres. Hence, we did
not relate any decreases in VAP incidence to an altered pop-
ulation mapping in terms of admission diagnosis.
During the baseline period, there was a VAP incidence of
12.9/1000 ventilator-days (a rate of 16 cases per 100
patients), which decreased to 9.28/1000 ventilator-days (a
rate of 11 cases per 100 patients) after the intervention per-
iod (p <0.05). DMV decreased from 11.1 to 6.4 days from
the baseline period to the intervention period (p <0.05).
The use of the full bundle was associated with an inci-
dence risk ratio of VAP of 0.78 (95% CI 0.15–0.99), delaying
onset of VAP from a median of 6–9 days.
Compliance for each variable of the care bundle varied for
all patients included in the study (Fig. 1). The highest compli-
ance was achieved regarding not changing ventilator circuits
unless necessary (34%; 301/885) and performing sedation
control (27%; 239/885) (p 0.20). On the other hand, intra-
cuff pressure control was consistently performed only in
18% (159/885) of opportunities, followed by oral care (21%;
186/885) and hand hygiene (19%; 188/885), which revealed
the lowest levels of compliance. When only signiﬁcant vari-
ables were taken in account, excluding all the cases where
compliance was not recorded and including only variables
with an OR < 1, overall compliance in VAP patients was
reduced to 9.3% (82/885).
In the intervention period, the risk of developing VAP was
signiﬁcantly reduced, when hand hygiene was performed (OR
0.35; 95% CI 0.11–0.68), and the same association was found
with intra-cuff pressure control (OR 0.21; 95% CI 0.25–0.92)
and oral hygiene (OR 0.23; 95%CI 0.17–0.75). The bundle
variable that appears to have less impact on the risk of
developing VAP is not changing the ventilator tubings unless
necessary (Fig. 2).
When analysing the number of VAP cases through time
(see Supplementary material, Data S4), one can observe a
majority of cases (60%) occurring before the seventh DMV.
In the intervention period, where full adherence to the
ﬁve evidence-based interventions of the care bundle was
recorded, the DMV was considerably reduced, as well as
ICU LOS (Fig. 3).
In all, 10.5% (93/885) of daily compliance records were
mssing. Early-onset VAP cases were to some extent affected
by the care bundle compliance (Fig. 4). A rate of 0.7% (6/885)
was observed, of which 0.5 episodes/1000 ventilator-days
TABLE 1. Demographic background of the study population
(baseline and intervention)
Baseline Intervention
Demographic details
n (patients) 149 885
Age, years (mean ± SD) 59 ± 18 66 ± 18
Sex, male (%) 69 65
APACHE II at admission mean ± SD 18 ± 8.6 17 ± 3.5
Co-morbidities (%)
Chronic obstructive pulmonary disease N/A 15
Cardiomyopathy N/A 11
Chronic renal failure N/A 4
Background on admission (%)
Medical 51 52
Surgical 38 33
Trauma* 11 15
APACHE II, Acute Physiology and Chronic Health Evaluation; N/A, not available.
*Only referring to some centres.
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FIG. 1. Rates of compliance with bundle vari-
ables in the intervention period.
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occurred with full compliance and 1 episode/1000 ventilator-
days with partial compliance of the prevention care bundle.
Late-onset VAP, on the other hand, with a rate of 9.4% (83/
885), had an incidence of 2.9 episodes/1000 ventilator-days
for patients with the full care bundle. For cases with only
partial bundle compliance (less than ﬁve measures), a VAP
incidence of 19.5 episodes/1000 ventilator-days was
observed.
Discussion
This is the ﬁrst study to validate a European care bundle for
VAP prevention [6]. In a long-term follow up, it was difﬁcult
to maintain high levels of compliance (see Supplementary
material, Data S5), demonstrating the importance of continu-
ous education of healthcare workers. Multidisciplinary efforts
combining doctors and other healthcare workers are
required.
The ﬁve speciﬁc care bundle variables used in our
approach were selected by an expert multidisciplinary group,
and each of them has been found in a previous study to be
associated with a decrease in the rate of VAP [6]. Our ﬁnd-
ings demonstrate a reduction of 4 days in ICU LOS and
DMV, when compliance was highest, and during the interven-
tion period. The VAP rate and DMV decreased after the
intervention, when performing a comparative analysis of the
available data in the pre-intervention and post-intervention
periods.
These ﬁndings are particularly relevant, because it has
been reported that the occurrence of VAP increases the
duration of hospital stay by approximately 6 days [25] and
that costs have been estimated to be above $40 000 [26].
Wip and Napolitano [27] have reviewed the value of care
bundles to prevent VAP. They concluded that, although the
‘ventilator bundle’ is an effective method to reduce VAP
rates, it should be modiﬁed towards introducing speciﬁc pre-
ventive strategies with proven effect in reducing VAP.
We have scrutinized the different bundle variables inde-
pendently and related them to VAP risk (Fig. 2). This enabled
us to suggest that some variables may have more impact on
improving outcomes than others, even though they seem to
be the ones with lowest compliance rates. Hand hygiene
before manipulating airways, for example, has shown a strong
impact on reducing VAP risk, but it revealed a compliance of
Hand hygiene OR = 0.35 (0.12–0.99)
OR = 0.21 (0.07–0.60)
OR = 0.23 (0.08–0.65)
OR = 0.51 (0.25–1.00)
OR = 1.07 (0.56–2.03)
0.25 0.5 2 3 4
1
Reduces VAP risk Increases VAP risk
Cuff pressure control
Oral care
Sedation control
Circuit tubing change
FIG. 2. Ventilator-associated pneumonia (VAP) risk odds ratio for
each preventive measure.
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FIG. 3. Intensive-care unit length of stay
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FIG. 4. Ventilator-associated pneumonia (VAP) incidence (episodes/
1000 mechanical ventilation days) for early-onset and late-onset VAP
according to measure compliance—ﬁgures after the intervention.
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only 19%. Because we have used a method essentially based
on self-registration of compliance by the attending nurse,
biases in reporting should be taken into account.
A major strength of our study is that its design has
allowed the assessment of individual measures over a long
follow-up period. Four out of ﬁve preventive measures were
found to have beneﬁt in VAP prevention. Not changing the
ventilator circuits revealed no signiﬁcant impact in reducing
the rate of VAP, whereas the rest of the preventive strate-
gies contributed to the decline of VAP incidence. Although
an ‘all-or-nothing’ approach is the main rule of bundle appli-
cation [6], a close relationship was established between the
number of compliant variables and VAP rates. During the
intervention period, the measures that most impacted on
the risk of developing VAP were hand hygiene (OR = 0.35)
and oral care (OR = 0.23). Our evidence also suggests
higher impact of the care bundle on late-onset VAP than on
early-onset VAP.
Similar to the before-and-after study by Morris et al. [28],
our work acknowledges the importance of a quality-improve-
ment programme in embedding practice change within the
culture of a unit or organization. Morris et al.’ results [28]
have shown levels of compliance with the care bundle that
are close to 100% and also that this led to clear beneﬁts to
patients. Our approach, on the other hand, advocates the
possibility lower thresholds for compliance with a care bun-
dle still obtaining beneﬁt in patient outcomes. In the Resar
et al. study [29], the bundle was based on measures that
were checked three times every day. Our accomplishment
of hand hygiene is in accordance with other studies [30].
The decision of assuming the lowest compliance levels for
each day, and each patient, might have had a strong impact
on the overall compliance. A Hawthorne effect may have
represented potential bias. In general, it is commonly
accepted that a heavy change in daily practice would take a
while until it achieves its ﬁnal goal. Indeed, our study may
conﬁrm what was suggested by Resar et al. [29] that a ‘chan-
ged delivery system’ and ‘chain reaction’ of increased atten-
tion to the patients leads to beneﬁts in patient outcomes.
Hence, even though we acknowledge that external factors
can be present, one can still explain why such a low compli-
ance level was still associated with a decrease in the rate of
VAP, DMV and ICU LOS.
Conclusions
Signiﬁcant improvements in outcomes can be achieved with
high compliance in implementing a care bundle package for
VAP prevention. This study shows that even though the
bundle approach was difﬁcult to maintain long term, signiﬁ-
cant beneﬁts were documented, even with low degrees of
compliance. Efforts should be concentrated in continuous
education of healthcare workers to maintain high levels of
compliance.
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